Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments

Executive Summary

After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.

You may also be interested in...



FDA’s Advisory Committees Just Can’t Say “No”

Who says an advisory committee stop is a risky proposition? FDA’s advisors have voted in favor of approval on each of the last 12 products they’ve reviewed.

Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

The latest drug development news and highlights from our FDA Performance Tracker.

Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say

Using a clinical trial originally designed for safety to support an efficacy superiority claim poses unique challenges that can make reliance upon a single study for regulatory purposes potentially risky.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS118863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel